Innovative Medicine
-
Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis
XALIA is First Prospective Study to Confirm Benefit of a Non-Vitamin K Antagonist Oral Anticoagulant (NOAC) for Treating Deep Vein Thrombosis in Routine Clinical Practice, Adds to More than 91,000 Patients Enrolled in Real-World Studies -
-
DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and immunomodulatory agent -
Largest Schizophrenia and Schizoaffective Disorder Caregiver Survey Reveals Overwhelming Burden and Inadequate Assistance
Findings Highlight Need for Education and More Support for Caregivers -
Janssen Announces Global License and Development Rights Agreement with Hanmi Pharmaceutical for Novel Clinical Stage Biologic to Treat Diabetes and Obesity
Novel Oxyntomodulin-Based Therapy Bolsters Janssen’s Metabolism Portfolio -
-
First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced
Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy -
U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Patients with Unresectable or Metastatic Liposarcoma or Leiomyosarcoma, Two Common Subtypes of Soft Tissue Sarcoma
Approval based on largest Phase 3 study conducted to date in this patient population -
Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn’s Disease
Efficacy and Safety Results from First STELARA® Phase 3 Induction Study (UNITI-2)
